THE GOAL OF THIS PROJECT WILL BE TO SCREEN NEW DERIVATIVES OF L-ASCORBIC ACID ADDUCTS CLASSIFIED AS METHYLFURYLBUTYROLACTONES, ALSO REFERRED TO AS NAFOCARE B.

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$50,000.00
Award Year:
1985
Program:
SBIR
Phase:
Phase I
Contract:
n/a
Agency Tracking Number:
3007
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
American Biotechnology Co., In
7658 Standish Place, Suite 107, Rockville, MD, 20855
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
ROBERT W. VELTRI
PRINCIPAL INVESTIGATOR
(301) 294-9553
Business Contact:
() -
Research Institution:
n/a
Abstract
THE GOAL OF THIS PROJECT WILL BE TO SCREEN NEW DERIVATIVES OF L-ASCORBIC ACID ADDUCTS CLASSIFIED AS METHYLFURYLBUTYROLACTONES, ALSO REFERRED TO AS NAFOCARE B. WORKING IN COLLABORATION WITH A SYNTHETIC ORGANIC CHEMISTRY GROUP AT WEST VIRGINIA UNIVERSITY, WE HAVE DETERMINED THAT THE PARENT COMPOUND, MFBL, HAS EXTENSIVE IMMUNE POTENTIATING ACTIVITY. OUR PROJECT WILL ANALYZE FIVE NEW DERIVATIVES OF L-ASCORBIC ACID IN AN ATTEMPT TO VERIFY WHICH PROSTHETIC GROUPS OTHER THAN THE BUTYROLACTONE STRUCTURE ARE CRITICAL TO BIOLOGICAL ACTIVITY. IN ADDITION, WE HOPE TO DISCOVER NEW SYNTHETIC IMMUNE BIOLOGICAL RESPONSE MODIFIERS. ALL TEST COMPOUNDS WILL BE SCREENED PRESUMPTIVELY USING THE MOUSE LYMPHOCYTE STIMULATION ASSAY. IF THE COMPOUND IS POSITIVE FOR ACTIVITY, FURTHER CONFIRMATORY IMMUNOASSAYS WILL BE PERFORMED USING T-CELL, B-CELL, AND MACROPHAGE EFFECTOR CELLS.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government